Zhao Zhite, Jing Yuming, Xu Zhicheng, Zhao Hongfan, He Xinglin, Lu Tong, Bai Jianhui, Qin Weijun, Yang Lijun
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
The Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xi'an, Shaanxi 710000, China.
Int J Biol Sci. 2025 Apr 13;21(6):2880-2890. doi: 10.7150/ijbs.109638. eCollection 2025.
Prostate cancer (PCa) is the second most common malignant tumor in men worldwide, particularly castration-resistant prostate cancer (CRPC), for which enzalutamide (Enz) resistance is of particular concern. Modifications to histone methylation and acetylation patterns are closely associated with resistance to Enz in these patients. As PCa progresses, cancer cells alter their histone modification patterns, leading to a reduction in Enz treatment efficacy. Signaling pathways in the tumor microenvironment regulate gene expression by affecting the activity of histone-modifying enzymes, further affecting the efficacy of Enz. This review summarizes recent research about changes in histone modification patterns that occur in drug resistance-related genes at different stages of PCa and explores the potential use of combination therapies for reversing this process, providing insights into novel treatment strategies to improve the clinical efficacy of Enz.
前列腺癌（PCa）是全球男性中第二常见的恶性肿瘤，尤其是去势抵抗性前列腺癌（CRPC），对其而言，恩杂鲁胺（Enz）耐药性尤为令人关注。组蛋白甲基化和乙酰化模式的改变与这些患者对恩杂鲁胺的耐药性密切相关。随着前列腺癌的进展，癌细胞会改变其组蛋白修饰模式，导致恩杂鲁胺治疗效果降低。肿瘤微环境中的信号通路通过影响组蛋白修饰酶的活性来调节基因表达，进而进一步影响恩杂鲁胺的疗效。本综述总结了前列腺癌不同阶段耐药相关基因中组蛋白修饰模式变化的最新研究，并探讨了联合治疗逆转这一过程的潜在用途，为提高恩杂鲁胺临床疗效的新治疗策略提供见解。
